Hypertrophy clinical trials

Explore recruiting hypertrophy clinical trials.

Recruiting hypertrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypertrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 12-month, interventional, open-label, phase 4 study in Europe (SHINE) to investigate the course of synovial hypertrophy as detected by joint ultrasound and MRI in patients with haemophilia A on efanesoctocog alfa prophylaxis.

Sweden, Italy, Norway, Spain

Therapeutic use (Phase IV) EU CTIS Study details

SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon®

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial

Austria, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Timely recovery after subclinical heart failure

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

SGLT2 INHIBITION (DAPAGLIFLOZIN) IN DIABETIC AND NON-DIABETIC HEMODIALYSIS PATIENTS WITH AND WITHOUT RESIDUAL URINE VOLUME: A PROSPECTIVE RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PHASE II TRIAL

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Hypertrophy trials by city

Hypertrophy in Toronto Hypertrophy in Vancouver Hypertrophy in Montreal Hypertrophy in Calgary Hypertrophy in Edmonton Hypertrophy in Ottawa Hypertrophy in Winnipeg Hypertrophy in Quebec City Hypertrophy in Hamilton Hypertrophy in Kitchener Hypertrophy in London Hypertrophy in Halifax Hypertrophy in New York Hypertrophy in Los Angeles Hypertrophy in Chicago Hypertrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease